Anavex Life Sciences Stock Tumble 38% on Rett Syndrome Trial Disappointment
Anavex Life Sciences, a clinical-stage biopharmaceutical company, experienced a significant setback on Tuesday as its stock plummeted by approximately 38% in premarket trading. This sharp...
